[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Precision Biosciences Inc (DTIL)

Precision Biosciences Inc (DTIL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 165,391
  • Shares Outstanding, K 25,802
  • Annual Sales, $ 34,260 K
  • Annual Income, $ -45,720 K
  • EBIT $ -39 M
  • EBITDA $ -37 M
  • 60-Month Beta 1.30
  • Price/Sales 4.55
  • Price/Cash Flow N/A
  • Price/Book 2.05

Options Overview Details

View History
  • Implied Volatility 314.01% (+72.91%)
  • Historical Volatility 67.20%
  • IV Percentile 50%
  • IV Rank 22.39%
  • IV High 1,350.68% on 03/11/26
  • IV Low 14.92% on 12/16/25
  • Expected Move (DTE 12) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 62
  • Volume Avg (30-Day) 81
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 1,664
  • Open Int (30-Day) 1,112
  • Expected Range 6.50 to 6.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.50
  • Number of Estimates 1
  • High Estimate $-0.50
  • Low Estimate $-0.50
  • Prior Year $-2.13
  • Growth Rate Est. (year over year) +76.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.00 +8.33%
on 06/03/26
8.59 -24.33%
on 05/13/26
-0.95 (-12.75%)
since 05/05/26
3-Month
4.38 +48.40%
on 03/06/26
8.59 -24.33%
on 05/13/26
+1.97 (+43.49%)
since 03/05/26
52-Week
3.53 +84.14%
on 02/05/26
8.82 -26.30%
on 10/29/25
+1.37 (+26.71%)
since 06/05/25

Most Recent Stories

More News
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

- New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts...

DTIL : 6.50 (+1.40%)
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026

- Webcast with Hepatitis B experts to discuss new biopsy and clinical data from the ongoing ELIMINATE-B trial in chronic hepatitis B - ...

DTIL : 6.50 (+1.40%)
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting

– New preclinical data show PBGENE-DMD drove up to a 3x higher dystrophin protein restoration in skeletal muscle and up to 12x higher in respiratory muscle in early-juvenile mice compared to late-juvenile...

DTIL : 6.50 (+1.40%)
Precision BioSciences: Q1 Earnings Snapshot

Precision BioSciences: Q1 Earnings Snapshot

DTIL : 6.50 (+1.40%)
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update

- Continued advancement of the Phase 1/2a ELIMINATE-B trial of PBGENE-HBV across multiple dosing cohorts; Late-Breaking poster presentation for PBGENE-HBV accepted at European Association...

TGTX : 40.16 (-0.99%)
DTIL : 6.50 (+1.40%)
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet...

DTIL : 6.50 (+1.40%)
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study

- Arkansas Children’s Hospital activated as the first clinical trial site and now enrolling patients in the FUNCTION-DMD study of PBGENE-DMD -

DTIL : 6.50 (+1.40%)
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet...

DTIL : 6.50 (+1.40%)
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies...

DTIL : 6.50 (+1.40%)
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026

- Late-breaking poster presentation to highlight new biopsy data demonstrating elimination and inactivation of cccDNA from the ongoing Phase 1 ELIMINATE-B trial in chronic hepatitis B -...

DTIL : 6.50 (+1.40%)

Business Summary

Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina.

See More

Key Turning Points

3rd Resistance Point 7.03
2nd Resistance Point 6.76
1st Resistance Point 6.63
Last Price 6.50
1st Support Level 6.24
2nd Support Level 5.97
3rd Support Level 5.84

See More

52-Week High 8.82
Fibonacci 61.8% 6.80
Last Price 6.50
Fibonacci 50% 6.17
Fibonacci 38.2% 5.55
52-Week Low 3.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.